Acute Crit Care.  2019 May;34(2):165-169. 10.4266/acc.2017.00045.

Acute fulminant myocarditis following influenza vaccination requiring extracorporeal membrane oxygenation

• Kim YJ
• Bae JI
• Ryoo SM
• Kim WY

• KMID: 2449372
• DOI: http://doi.org/10.4266/acc.2017.00045

Abstract

The inactivated influenza vaccination is generally safe with mostly mild side effects. We report a rare but fatal adverse event following influenza vaccination. A previously healthy 27-year-old woman who received the influenza vaccination 3 days before presenting to the emergency department had rapidly aggravating dyspnea and mental deterioration. She was diagnosed as having acute fulminant myocarditis with refractory cardiogenic shock, which was successfully managed with veno-arterial extracorporeal membrane oxygenation. The cardiac function of the patient recovered in 3 weeks.

Keyword

adverse event; cardiogenic shock; extracorporeal membrane oxygenation; influenza vaccines; myocarditis

MeSH Terms

Adult
Dyspnea
Emergency Service, Hospital
Extracorporeal Membrane Oxygenation*
Female
Humans
Influenza Vaccines
Influenza, Human*
Myocarditis*
Shock, Cardiogenic
Vaccination*
Influenza Vaccines

Figure

• 

  Figure 1. Serial changes of vital signs and lactic acid level for 10 hours after emergency department (ED) presentation. ECMO: extracorporeal membrane oxygenation; ICU: intensive care unit.

• 

  Figure 2. Serial chest X-rays during hospitalization. (A) Chest X-ray showed diffuse ground glass opacities on both lung fields at 4 hours after emergency department presentation. (B) Chest X-ray after insertion of extracorporeal membrane oxygenation and intubation at emergency department. (C) Chest X-ray after recovery on the 9th day of hospitalization.

• 

  Figure 3. Representative cardiovascular magnetic resonance findings in a patient with acute myocarditis. (A) Short-axis T2 map revealed an increased global myocardial T2 value of 68–72 ms in this patient. (B) Late gadolinium enhancement shows mild diffuse midwall enhancement in the left ventricular (LV) myocardium.

Reference

1. Korea Centers for Disease Control and Prevention. Korea Centers for Disease Control and Prevention (KCDC) web [Internet]. Cheongju: Korea Centers for Disease Control and Prevention;2017. [cited 2017 Oct 19]. Available from: http://cdc.go.kr/CDC/mobile/intro/CdcKrIntro0505.jsp?menuIds=HOME001-MNU1154-MNU2557-MNU2487&cid=76303.

2. Nichol KL, Margolis KL, Lind A, Murdoch M, Mc-Fadden R, Hauge M, et al. Side effects associated with influenza vaccination in healthy working adults: a randomized, placebocontrolled trial. Arch Intern Med. 1996; 156:1546–50.

3. de Meester A, Luwaert R, Chaudron JM. Symptomatic pericarditis after influenza vaccination: report of two cases. Chest. 2000; 117:1803–5.

4. Cheng MP, Kozoriz MG, Ahmadi AA, Kelsall J, Paquette K, Onrot JM. Post-vaccination myositis and myocarditis in a previously healthy male. Allergy Asthma Clin Immunol. 2016; 12:6.

5. Singh K, Marinelli T, Horowitz JD. Takotsubo cardiomyopathy after anti-influenza vaccination: catecholaminergic effects of immune system. Am J Emerg Med. 2013; 31:1627. e1-4.

6. Streifler JJ, Dux S, Garty M, Rosenfeld JB. Recurrent pericarditis: a rare complication of influenza vaccination. Br Med J (Clin Res Ed). 1981; 283:526–7.

7. Rosenberg M, Sparks R, McMahon A, Iskander J, Campbell JD, Edwards KM. Serious adverse events rarely reported after trivalent inactivated influenza vaccine (TIV) in children 6-23 months of age. Vaccine. 2009; 27:4278–83.

8. Lanza GA, Barone L, Scalone G, Pitocco D, Sgueglia GA, Mollo R, et al. Inflammation-related effects of adjuvant influenza A vaccination on platelet activation and cardiac autonomic function. J Intern Med. 2011; 269:118–25.

9. Engler RJ, Nelson MR, Collins LC Jr, Spooner C, Hemann BA, Gibbs BT, et al. A prospective study of the incidence of myocarditis/pericarditis and new onset cardiac symptoms following smallpox and influenza vaccination. PLoS One. 2015; 10:e0118283.